Please check the following:
- {{x.value}}
FREE membership
FREE membership
Join Intelligent Investor today
{{ twilioFailed ? 'SMS Code Failed to Send…' : 'Enter verification code' }}
Please enter the 5 digit verification code sent to "{{user.DayPhone}}" Change number
We cannot send you a verification code via SMS to "{{user.DayPhone}}" Change number
{{ completedStep1 ? 'Authentication & Security' : content.trialHeading.replace('{0}', user.FirstName) }}
Please enter your mobile number and press send to receive a text message with a verification code.
{{ content.upgradeHeading.replace('{0}', user.FirstName) }}
The email address you entered is registered with InvestSMART
Please login to continue
Thank you
We have sent you an email with the details of your registration.
Purchase order
Sign up
Log in
Looks you are already a member. Please enter your password to proceed
{{ upgradeCTAText }}
Updating information
Please wait ...
Your membership to InvestSMART Group recently failed to renew.
Please make sure your payment details are up to date to continue your membership.
Having trouble renewing?
Please contact Member Services on support@investsmart.com.au or 1300 880 160
You've recently updated your payment details.
It may take a few minutes to update your subscription details, during this time you will not be able to view locked content.
If you are still having trouble viewing content after 10 minutes, try logging out of your account and logging back in.
Still having trouble viewing content?
Please contact Member Services on support@investsmart.com.au or 1300 880 160
Please click on the ACTIVATE button to activate your Intelligent Investor 15-day free trial
Please click on the ACTIVATE button to finalise your membership
Log in
Upgrade Today
Unsuccessful registration
Registration for this event is available only to Eureka Report members. View our membership page for more information.
Registration for this event is available only to Intelligent Investor members. View our membership page for more information.
{{eventFunction.Name}}
{{eventFunction.EventTypeName}}
{{eventFunction.StartDate}}
{{eventFunction.EventTimings}}
{{eventFunction.VenueName}}
{{ t.Cost === 0 ? "FREE" : "$" + t.Cost.toFixed(2) }}
Quantity *
- You are already registered for this event.
- This event is already full.
- Please select a quantity for at least one ticket.
- {{ i }}
Forgotten password
Please enter your email address below to request a new password
Congratulations!
You now have free access to InvestSMART, we look forward to helping you on your financial journey.
You now have access to Free Eureka Report Insights, We look forward to helping you on your financial journey.
You now have access to Intelligent Investor Free Insights. We look forward to helping you build a market beating stock portfolio.
Looking for more…
Intelligent Investor Membership
15-day Free Trial
- Indepth analysis of ASX listed shares
- BUY, Hold and Sell Recommendations
- Ideas Lab
- Special Reports
No thanks
Looking for more…
Eureka Report Membership
15-day Free Trial
- Alan Kohler’s Weekend Briefing
- Interviews with CEO’s & top influencers
- Money Cafe and Talking Finance
- Super Advice and Q&A with Ask Alan
No thanks
Healius Limited (ASX: HLS) - Share Price and Research
Current share price for HLS : $1.205 0.005 (0.41%)
Healius Limited (HLS), an ASX-listed company, has been leading healthcare companies, committed to supporting quality, affordable and accessible healthcare for all Australians. Today, Healius has two diagnostics businesses, pathology, and imaging.
HLS General Information +
| ASX Code | HLS |
| Website | http://www.healius.com.au |
| Industry/Sector | Health Care Services |
| Market Cap ($M) | 874 |
| HLS Share Price | $1.205 |
| Day High | $1.220 |
| Day Low | $1.190 |
| Last Close | $1.210 |
| HLS Share Price Movement | $0.00 ( 0.41% ) |
Prices as at 16:40, 19 Apr 2024
+Security prices are delayed by at least 20 minutes and are indicative only.
HLS Related Research
Healius Limited (HLS) Upcoming Dividends & Yields
| Distribution Type | Dividend | Franking | Ex-dividend date | Payment date | Current Price+ | Price 7D Avg | Dividend Yield |
|---|---|---|---|---|---|---|---|
| HFResult | 6¢ | 100% | 7 Sep 2022 | 21 Sep 2022 | $1.205 | $1.230 | 2.74% |
| Result | 10¢ | 100% | 24 Mar 2022 | 5 Apr 2022 | $1.205 | $1.230 | 2.74% |
| HFResult | 6.75¢ | 100% | 13 Sep 2021 | 8 Oct 2021 | $1.205 | $1.230 | 2.74% |
See all dividends from Healius Limited (HLS) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.
Healius Limited (HLS) Recent ASX Announcements
| Headline | Annoucement date/time+ | Price at announcement+ | Current price+ | Price 7D Avg | Gain/Loss |
|---|---|---|---|---|---|
| Becoming a substantial holder | 26 Mar 2024 8:25AM | $1.290 | $1.205 | $1.230 | fallen by 6.59% |
| Change in substantial holding | 22 Mar 2024 3:32PM | $1.255 | $1.205 | $1.230 | fallen by 3.98% |
| Ceasing to be a substantial holder | 20 Mar 2024 6:11PM | $1.205 | $1.205 | $1.230 | fallen by 0% |
- + Company announcements and prices are delayed by at least 20 minutes. Prices are indicative only.
See all ASX announcements from Healius Limited (HLS) or use our ASX Announcements tool to search for announcements across all ASX-listed securities.
HLS Financial Summary
| Year to Jun | NPAT | EPS | EPS chg (%) | PER | DPS | Yield (%) | Franking (%) |
|---|---|---|---|---|---|---|---|
| 2025F | $48.59 | $6.53 | 2,004.70% | 18.53 | 5.00 | 4.13% | 100.0% |
| 2024F | $2.31 | $0.31 | -92.90% | 390.32 | 0.00 | 0.00% | 100.0% |
| 2023A | $25.70 | $4.34 | -91.70% | 69.53 | 0.00 | 0.00% | 100.0% |
HLS Peer Comparison
| Company | Mkt Cap | EPS Growth (%) | P/E (%) | Dividend Yield (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2023 A | 2024 F | 2025 F | 2023 A | 2024 F | 2025 F | 2023 A | 2024 F | 2025 F | ||
| Australian Clinical Labs (ACL) | $486M | -0.8335 | -0.0326 | 0.2722 | 15.7106 | 16.2399 | 12.7648 | 5.81% | 3.32% | 4.77% |
| Healius (HLS) | $875M | -0.8248 | -0.9826 | 37.4000 | 13.9629 | 803.3333 | 20.9201 | 0.00% | 0.00% | 3.32% |
| Integral Diagnostics (IDX) | $573M | -0.2212 | 0.2929 | 0.4908 | 36.2426 | 28.0320 | 18.8028 | 2.45% | 2.56% | 3.78% |
| Sonic Healthcare (SHL) | $12,486M | -0.5207 | -0.2079 | 0.3159 | 17.9241 | 22.6295 | 17.1971 | 4.00% | 3.67% | 4.12% |
HLS Market Comparison
| Earnings | P/E Ratio | P/B Ratio | P/E Growth | |
|---|---|---|---|---|
| Company | 0.71 | 66.40 | 0.49 | 0.00 |
| Market | 0.65 | 16.60 | 1.40 | 1.29 |
| Sector | 0.84 | 33.30 | 2.35 | 2.42 |
HLS Directors
| Name | Position | Start Date |
|---|---|---|
| Mr Paul Anderson | Chief Executive Officer, Managing Director | 5 Mar 2024 |
| Dr Michael Philip Stanford | Non-Executive Director | 1 Sep 2023 |
| Professor John Mattick | Non-Executive Director | 31 Mar 2022 |
| Mr Gordon Richard Davis | Non-Executive Director | 3 Aug 2015 |
| Ms Kathryn (Kate) Mary McKenzie | Non-Executive Director | 25 Feb 2021 |
| Ms Sally Evans | Non-Executive Director | 21 Aug 2018 |
| Mr Charlie Taylor | Non-Executive Director | 20 Mar 2023 |
| Mr Ravi Jeyaraj | Non-Executive Director | 28 Nov 2023 |
Healius Limited (HLS) Changes in Directors' Interest & Trades
| Date of change | Director | Buy/Sell | Security Type | Qty | Trade Price | Value |
|---|---|---|---|---|---|---|
| 15 Mar 2024 | EVANS, Sally | Exercise | Related Securities | 16,450 | $1.520 | $25,000.000 |
| 15 Mar 2024 | TAYLOR, Charlie | Buy | Direct Shares | 16,450 | $1.520 | $25,000.000 |
| 15 Mar 2024 | TAYLOR, Charlie | Exercise | Related Securities | 16,450 | $1.520 | $25,000.000 |
See all changes in directors' interest & trades for Healius Limited (HLS) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.
HLS Management
| Name | Position |
|---|---|
| Paul Anderson | Chief Financial Officer |
| Mary Weaver | Company Secretary |
| Stephen Humphries | Company Secretary |
| Jan van Rooyen | Group Executive |
| Janet Payne | Group Executive Corporate Affairs |
| Mark Neeham | Group Executive Government Affairs |
| John McKechnie | Group Executive Pathology |
| Jon Eide | Group Executive, Commercial and Customer |
| Phil Lucas | Group Executive, Lumus Imaging |
| Arjun Narang | Group Executive, Operations Transformation |
| Prasad Arav | Group Executive. Digital and Technology |
HLS Substantial Shareholders
Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Healius Limited (HLS). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.
| Holding | Name |
|---|---|
| 79,312,419 (13.92%) | Perpetual Limited |
| 54,173,608 (9.51%) | Australian Retirement Trust Pty Ltd |
| 45,549,533 (7.84%) | Tanarra Capital Australia Pty Ltd |
| 35,155,034 (6.17%) | Host-Plus Pty Limited |
| 30,485,918 (6.04%) | Dimensional Entities |
| 34,968,120 (6.02%) | State Street Corporation and its subsidiaries |
| 29,374,935 (5.06%) | Mitsubishi UFJ Financial Group, Inc |
| 29,374,935 (5.06%) | First Sentier Investors Holdings Pty Limited |
| 28,642,884 (5.03%) | United Super Pty Ltd |
| 29,214,808 (5.03%) | Commonwealth Bank of Australia |
| 29,004,002 (5%) | Vanguard Group |
HLS Calendar of Events
| Date | Event |
|---|---|
| 25 February 2025 | Report (Interim) |
| 24 September 2024 | Report (Annual) |
| 28 August 2024 | Report (Prelim) |
FAQs about Healius Limited (HLS)
What is the current share price of Healius Limited (HLS)?
Healius Limited's (HLS) current share price is $1.21. This constitutes a price movement of 2.03% when compared to the share price 7 days ago and is -62.92% below HLS's 12-month high of $3.25 per share. Prices are delayed by at least 20 minutes.
What is the share price movement for Healius Limited (HLS)?
Relative to the previous close share price of $1.21, Healius Limited's (HLS) current share price of $1.21 constitutes a movement of $0.00 or -0.41%. Healius Limited's (HLS) share price movement is -2.03% when compared to 7 days ago and is -62.92% below HLS's 52-week high of $3.25.
What is the 52-week high share price for Healius Limited (HLS)?
Healius Limited's (HLS) 52-week high is $3.25 which was reached on 8 Jun 2023. Relative to this, HLS's current share price of $1.21 constitutes a -$2.05 or -62.92% drop since that high of $3.25 per HLS share.
What is the 52-week low share price for Healius Limited (HLS)?
Healius Limited's (HLS) 52-week low is $1.11 which was reached on 29 Feb 2024. Relative to this, HLS's current share price of $1.21 constitutes a $0.10 or 8.56% gain since that low of $1.11 per HLS share.
What is the daily average trading volume for Healius Limited (HLS)?
Over the last 12 months, Healius Limited (HLS) has a daily average trading volume of 1,977,279 HLS shares per day.
What is the dividend yield for Healius Limited (HLS)?
Healius Limited (HLS) has a current dividend yield of n/a this year. Last year's dividend yield was 0%. The dividend yield for HLS is a ratio that tells you the percentage of Healius Limited's (HLS) share price that it pays out in dividends each year.
What was Healius Limited (HLS) last dividend payment?
Healius Limited (HLS) last dividend payment was $0.06 per share and was paid on 21 Sep 2022. This last HLS dividend included 100% franking.
What is the franking level for Healius Limited (HLS)?
Healius Limited (HLS) has a franking level of 100%. Franking represents the tax Healius Limited (HLS) has already paid on any profit it distributes to shareholders as a dividend.
When does Healius Limited (HLS) release its next Annual Report?
Healius Limited (HLS) will release its next Annual Report on 24 September 2024. Healius Limited's (HLS) last annual report was released on 26 Sep 2023. Click here to view Healius Limited's (HLS) last annual report.
In which sector is Healius Limited (HLS) classified?
Healius Limited (HLS) is classified as Health Care. Other companies in this sector include CSL Limited (CSL), Cochlear Limited (COH), ResMed Inc. (RMD), and Fisher & Paykel Healthcare Corporation Limited (FPH).
What is the price-to-earnings (P/E) ratio for Healius Limited (HLS)?
The price-to-earnings (P/E) ratio for Healius Limited (HLS) is 66.4. The price-to-earnings ratio, also known as P/E ratio, P/E, or PER, is the ratio of Healius Limited's (HLS) share price to its earnings per HLS share.
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Data shown on this website is sourced by Morningstar
© 2017 Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate,
complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892)
and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and,
if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest.
No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser.
Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.
What our members say about us
Proudly
We're here to help
Call 1300 880 160
Start a chat
Schedule a call
